Alpha 2.0
Login Register
» Articles » PMID: 35031767

Author Correction: The Foundations of Immune Checkpoint Blockade and the Ipilimumab Approval Decennial

Overview
Journal Nat Rev Drug Discov
Specialty Pharmacology
Date 2022 Jan 15
PMID 35031767
Authors
Alan J Korman
Sarah C Garrett-Thomson
Nils Lonberg
Affiliations
Soon will be listed here.
Citing Articles

Regulatory T cells in immune checkpoint blockade antitumor therapy.

Zhang A, Fan T, Liu Y, Yu G, Li C, Jiang Z Mol Cancer. 2024; 23(1):251.

PMID: 39516941 PMC: 11545879. DOI: 10.1186/s12943-024-02156-y.

Targeting PD-L1 in cholangiocarcinoma using nanovesicle-based immunotherapy.

Gondaliya P, Sayyed A, Yan I, Driscoll J, Ziemer A, Patel T Mol Ther. 2024; 32(8):2762-2777.

PMID: 38859589 PMC: 11405167. DOI: 10.1016/j.ymthe.2024.06.006.

Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis.

Liu Y, Li S, Chen L, Lin L, Xu C, Qiu H Front Immunol. 2024; 15:1341596.

PMID: 38380323 PMC: 10876793. DOI: 10.3389/fimmu.2024.1341596.

Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses.

Zhang S, Zhao L, Guo M, Liu P, Li S, Xie W J Immunother Cancer. 2023; 11(7).

PMID: 37419511 PMC: 10347457. DOI: 10.1136/jitc-2023-006785.

Identification of the Immune Subtype of Hepatocellular Carcinoma for the Prediction of Disease-Free Survival Time and Prevention of Recurrence by Integrated Analysis of Bulk- and Single-Cell RNA Sequencing Data.

Fu J, Lei X Front Immunol. 2022; 13:868325.

PMID: 35734185 PMC: 9207181. DOI: 10.3389/fimmu.2022.868325.